华法林抗凝治疗中出血和血栓栓塞性不良反应及相关因素探讨

被引：14

作者：

侯爱军 ^{[1
]}

许俊堂 ^{[1
]}

郭继鸿 ^{[1
]}

王付龙 ^{[2
]}

申玉良 ^{[3
]}

机构：

[1] 北京大学人民医院心电生理室

[2] 解放军医院

[3] 河北省邯郸市中心医院

来源：

中国实用内科杂志 | 2006年 / 02期

关键词：

华法林; 出血; 血栓栓塞; 国际标准化比值;

D O I：

暂无

中图分类号：

R453 [药物疗法、化学疗法];

学科分类号：

摘要：

目的研究华法林抗凝治疗过程中出血和血栓栓塞性不良反应并识别相关危险因素。方法观察北京大学人民医院2001-042003-11抗栓门诊华法林使用大于4周患者的出血和血栓栓塞事件,事件分为小事件、严重事件和威胁生命或致命性事件,应用多种统计方法分析出血和血栓栓塞事件发生情况及相关危险因素。结果128例服用华法林患者,平均年龄67岁(2583岁),34例(占26·6%)共发生41次出血事件,严重和致命性的血栓栓塞事件5例(占3·9%)。年龄、肝硬化与出血事件显著相关(P=0·040,P=0·014)。结论出血是华法林抗凝治疗最主要的不良反应,而年龄、肝硬化是出血事件的重要危险因素。

引用

页码：133 / 135

页数：3

共 13 条

[1] E-volution of blood coagulation and fibrinolysis parameters after ab-rupt versus gradual withdrawal of acenocoumarol in patients with venous thromboembolism:a double blind randomized study. Tardy B,Tardy-Poncet B,Laporte-Simitsidis S,et al. British Journal of Haematology . 1997
[2] Bleeding in outpa-tients treated with warfarin:relation to the prothrombin time and important remediable lesions. Landefeld CS,Rosenblatt MW,Goldman L. The American Journal of Medicine . 1989
[3] Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation:a multicenter,prospective,randomized trial. Takenori Y. Stroke . 2000
[4] Assessment of a bleeding risk index in two cohorts of patients trea-ted with oral anticoagulants. van der Meer FJM,Rosendaal FR,Vandenbroucke JP,et al. Thrombosis and Haemostasis . 1996
[5] Withdrawal of warfarin after deep vein thrombosis:effects of a low fixed dose on rebound thrombin generation. Ascani A,Iorio A,Agnelli G. Blood Coagulation and Fibrinolysis . 1999
[6] Management of oral anticoagu-lants in the treatment of venous thromboembolism. Pinede L,Duhaut P,Ninet J. European Journal of Internal Medicine . 2001
[7] Warfarin,aspirin,or both after myocardial infarction. Hurlen M,Abdelnoor M,Smith P,et al. The New England Journal of Medicine . 2002
[8] Warfarin and as-pirin versus aspirin alone in patients with acute myocardial infarc-tion:a pilot study. Zibaeenezhad MJ,Mowla A,Sorbi MH,et al. Angiology . 2004
[9] Warfarin withdrawal-pharmacokinetic pharmacodynamic considerations. Palaretti G,Legnani C. Clinical Pharmacokinetics . 1996
[10] Oral anticoagulation and risk of death:a medical record linkage study. Oden A,Fahlen M. British Medical Journal . 2002

← 1 2 →